Search clinical trials for: FG-3019

Total 380 results

FibroGen

Terminated

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis

United States
FibroGen

Completed

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Diabetes Mellitus

United States
FibroGen

Terminated

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, China, Australia, Korea, Republic of, Taiwan, Russian Federation, Hong Kong, Argentina, Chile
FibroGen

Terminated

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

COVID-19

United States
FibroGen

Terminated

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, France, United Kingdom, Korea, Republic of, Lebanon, Denmark, China, Italy, Spain, Serbia, Germany, Netherlands, Czechia, Brazil, Poland, Argentina, Colombia, Dominican Republic, Georgia, Hungary, Ireland, Mexico, Peru, Switzerlan... and more
FibroGen

Completed

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Pancreatic Cancer
FibroGen

Completed

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer

United States
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD (LELANTOS-2)

Duchenne Muscular Dystrophy

United States, Spain, Canada, Australia, China, Italy, Belgium, France, Netherlands, Austria, United Kingdom
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) (LELANTOS-1)

Duchenne Muscular Dystrophy

United States, Belgium, Israel, Spain, Canada, Australia, Switzerland, United Kingdom, France, China, Netherlands, Italy, Austria, Czechia
FibroGen

Completed

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Diabetes Mellitus | Diabetic Nephropathy

United States
FibroGen

Completed

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis (FGCL-3019-049)

Idiopathic Pulmonary Fibrosis

United States
FibroGen

Terminated

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease

United States
FibroGen

Terminated

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Liver Fibrosis Due to Chronic Hepatitis B Infection

Hong Kong, Thailand
FibroGen

Terminated

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (MISSION)

Duchenne Muscular Dystrophy

United States
Guili Wang

Recruiting

Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material PLCL/Fg

Diabetic Foot

China
University of Minnesota

Completed

Health Wearables and College Student Health

Physical Activity | Technology | Intervention | Behavior Change | Young Adults

United States
FibroGen
AstraZeneca

Withdrawn

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Anemia Associated With Chronic Kidney Disease

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Chemotherapy Induced Anemia

United States
FibroGen

Completed

Study of FG-4592 in Subjects With Chronic Kidney Disease in China

Anemia in Chronic Kidney Disease

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
FibroGen

Completed

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis

Anemia

China
Atossa Therapeutics, Inc.

Completed

AT-301 Nasal Spray in Healthy Adults

Healthy

Australia
Astellas Pharma Inc

Completed

Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers

Healthy Volunteers

Japan
Novindiet Clinic
Tehran University of Medical Sciences; University of Nottingham

Completed

Effects of Moderate Consumption of Lean Fish on Weight Loss

Obesity | Overweight

Iran, Islamic Republic of
FibroGen

Completed

Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

Healthy Adult Subjects
Z Optics, Inc.

Not yet recruiting

Evaluation of Safety and Effectiveness of an IOL With a Virtual Aperture Optic

Cataract | Presbyopia | Intraocular Lens
Cognito Therapeutics, Inc.

Active, not recruiting

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Dementia, Alzheimer Type | Memory Disorders | Memory Impairment | Alzheimer Dementia | Memory Loss | Dementia, Mild | Memory Disorders, Age Related

United States
FibroGen
Peking University First Hospital; Peking Union Medical College Hospital; First... and other collaborators

Completed

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

Anemia in End Stage Renal Disease

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
FibroGen

Completed

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Pancreatic Cancer (Unresectable)

United States
FibroGen

Completed

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Anemia

China
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
Coherent Biopharma (Hefei) Co., Ltd.

Recruiting

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Cancer, Breast | Cancer of Pancreas | Cancer Colorectal | Cancer, Lung | Cancer of Esophagus

China, United States
FibroGen

Completed

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

CKD Anemia in Dialysis Participants

China
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Chronic Kidney Disease | Renal Anemia

Romania, Spain, Belgium, Germany, Norway, Slovakia, Denmark, Czechia
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
FibroGen
Astellas Pharma Inc

Completed

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

Anemia | Chronic Kidney Disease

United States
Cullinan Oncology, LLC
National Cancer Institute (NCI)

Terminated

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

France, Singapore, United States, China, Hong Kong
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Completed

A Study of SI-F019 in Healthy Participants

Healthy

China
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Nasopharyngeal Cancer | Epstein-Barr Virus Related Carcinoma

United States
Dolorgiet GmbH & Co. KG
d.s.h. statistical services GmbH; CenTrial GmbH

Completed

Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis

Actinic Keratosis Olsen Grade I/II

Germany
Deciphera Pharmaceuticals LLC

Active, not recruiting

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Advanced Malignant Neoplasm | Tenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis | Tenosynovial Giant Cell Tumor, Diffuse

United States, France, Spain, United Kingdom, Netherlands, Canada, Italy, Australia, Poland
PRAECIS Pharmaceuticals Inc.

Completed

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Tongji Hospital

Unknown

Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health. (COVID-19)

Coronavirus Disease 2019

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalating Study of BPI-3016 in Healthy Subjects

Healthy Subject

China
Meir Medical Center

Unknown

Levator Muscle Strength Evaluation

Ptosis

Israel
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer

Search clinical trials for: FG-3019

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations